Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy

Ronald de Wit, J Herrstedt, B Rapoport, AD Carides, M Elmer, C Schmidt, JK Evans, KJ Horgan

Research output: Contribution to journalArticleAcademicpeer-review

135 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)4105-4111
Number of pages7
JournalJournal of Clinical Oncology
Volume21
Publication statusPublished - 2003

Cite this